Marcel Karperien studied biology at Utrecht University. After graduation in 1991 he worked as a PhD-student at the Netherlands Institute for Developmental Biology and Stem Cell Research. He continued his career at the Leiden University Medical Center working on regulation of longitudinal bone growth and metabolic bone disorders. In 2007 he moved to the MIRA Institute for Biomedical Technology and Technical Medicine where he established the Department of Developmental BioEngineering. He is interested in developing new solutions for treating cartilage related disorders. His work is technology inspired and is characterized by a multidisciplinary approach. In his work in depth knowledge of the molecular and cellular biology of cartilage is combined with state of the art chemical- and nano-technology. Specific research topics are i) the identification of the molecular mechanisms underlying the pathophysiology of osteoarthritis, ii) the development of (stem) cell based strategies for repairing the damaged articular cartilage surface and iii) the development of new generations of biomaterials that can be used in a non-invasive manner for cell delivery in the diseased joint. Marcel Karperien has received awards from the American Society for Bone and Mineral Research (Young investigator award, travel grant awards), Dutch Society for Endocrinology (NVE), the European Calcified Tissue Society and the MIRA Institute for Biomedical Technology and Technical Medicine for his work. His work is supported by an unrestricted research grant from the Dutch Arthritis Foundation.
Microfabrication Technologies For Engineering a Joint on Chip
Thursday, 10 September 2020 at 11:30
Add to Calendar ▼2020-09-10 11:30:002020-09-10 12:30:00Europe/LondonMicrofabrication Technologies For Engineering a Joint on ChipOrgan-on-a-Chip, Tissue-on-a-Chip and Organoids Europe 2020 in Rotterdam, The NetherlandsRotterdam, The NetherlandsSELECTBIOenquiries@selectbiosciences.com
Osteoarthritis (OA) is a degenerative joint disease affecting more than 130.000.000 patients world-wide. The etiology of the disease is still poorly understood. While initially considered as a disease of cartilage it is now clear that the disease involves all tissues in the joint. A disease trigger in each of these tissues can initiate the onset of disease and each of these triggers converge over time in a similar disease presentation. Despite tremendous efforts in the recent past, the disease can still not be treated. It is believed that lack of translational power of currently used in vitro and in vivo animal models can at least in part this lack of success. It has also become clear that currently used animal models poorly reflect the complexity of human disease nor do they allow the detailed study of the complex interactions between the different joint tissues at various stages of disease. To address these shortcomings my group has started the development of a joint-on-chip. The joint-on-chip has a modular chip design (Piluso et al., 2019). We are engineering chips for each individual tissue, i.e. cartilage, subchondral bone, synovium, ligament and/or meniscus which together form the joint. The individual chips are connected to each other through blood vessel mimicking microfluidic channels as well as with a chip mimicking the intra-articular space. This latter chip will contain features allowing non-invasive imaging / sensing of inter tissue communication. Since movement is a critical and an essential feature in every joint, the individual chips can all be independently actuated mimicking both compression and shear stress. Prototype chips of the synovium and the cartilage including actuation have become available (Paggi et al., 2020). Additionally we developed various strategies for introducing cell laden membranes composed of natural polymers and/or tissue constructs in the chip. Finally, we have developed sensors that can assess local matrix metalloproteinase activity, a key factor driving joint degeneration on chip. In my presentation I will discuss various engineering aspects of our microfabrication technology platforms needed for recreating a representative and functional human joint. It is expected that these efforts will help us studying the pathophysiology of osteoarthritis and will accelerate the development of dearly needed osteoarthritis disease modifying treatments.
Add to Calendar ▼2020-09-09 00:00:002020-09-10 00:00:00Europe/LondonOrgan-on-a-Chip, Tissue-on-a-Chip and Organoids Europe 2020Organ-on-a-Chip, Tissue-on-a-Chip and Organoids Europe 2020 in Rotterdam, The NetherlandsRotterdam, The NetherlandsSELECTBIOenquiries@selectbiosciences.com
Add to Calendar ▼2020-09-10 11:30:002020-09-10 12:30:00Europe/LondonMicrofabrication Technologies For Engineering a Joint on ChipOrgan-on-a-Chip, Tissue-on-a-Chip and Organoids Europe 2020 in Rotterdam, The NetherlandsRotterdam, The NetherlandsSELECTBIOenquiries@selectbiosciences.com
